Elimination of hepatitis C virus infection among PWID
The beginning of a new era of interferon-free DAA therapy
Datos Bibliográficos
| ID | 14908792 |
|---|---|
| Autores | J Grebely (0000-0002-1833-2017, UNSW Sydney, autor de correspondencia), Julie Bruneau (0000-0002-3484-6456, Université de Montréal), Philip Bruggmann (0000-0002-0436-8895, Addiction Switzerland), Magdalena Harris (0000-0001-8718-8226, London School of Hygiene & Tropical Medicine), Matthew Hickman (0000-0001-9864-459X, University of Bristol), Tammy Rhodes (0000-0003-2400-9838, UNSW Sydney), Carla Treloar (0000-0002-8230-0386, UNSW Sydney) |
| Año | 2017 |
| Volumen | 47 |
| Páginas | 26-33 |
| Fecha de publicación | 2017-09-01 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | International Journal of Drug Policy (JOURNAL) |
| Identificadores de la revista | ISSN: 0955-3959 • E-ISSN: 1873-4758 |
| Editorial | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.drugpo.2017.08.001 |
| PMID | 28888558 |
| OpenAlex | W2751350641 |
| Idioma | EN |
| Citas recibidas | 18 |
| Referencias citadas | 105 |
Cronbach's alpha · Exploratory factor analysis · Family medicine · Hepatitis C · Hepatitis C virus · Preparedness · Prior authorization · Virus · Clinical Psychology · Hepatitis C virus research · HIV, Drug Use, Sexual Risk · HIV/AIDS Research and Interventions · Medicine · Nursing · Immunology · Internal Medicine
Evaluation of a person-centred, nurse-led model of care delivering hepatitis C testing and treatment in priority settings
Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective - a qualitative exploration
“I want to get better, but…”
Futuring a world without disease
Excitable models
Evaluation of contingency management as a strategy to improve HCV linkage to care and treatment in persons attending needle and syringe programs
Everybody living with a chronic disease is entitled to be cured”
How to think with models and targets
Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain
High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units
Elimination of hepatitis C virus infection among people who use drugs
Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada
Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs
HCV screening based on dried blood samples and linkage to care in people who use drugs
Transitioning from interferon-based to direct antiviral treatment options
Stigma is where the harm comes from”
Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era
Towards eliminating viral hepatitis”
The Spectrum of Engagement in HIV Care and its Relevance to Test-and-Treat Strategies for Prevention of HIV Infection
Hepatitis C treatment access and uptake for people who inject drugs
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs
Epidemiology and natural history of HCV infection
Hepatitis C virus treatment for prevention among people who inject drugs
‘I didn’t want to let it go too far.’ The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign
Factors Influencing Uptake of Rapid HIV and Hepatitis C Screening Among Drug Misusing Adult Emergency Department Patients
Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996–2015
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs
Tensions in relation
Dot-C
High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic
Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia
Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine
Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics
Recommendations for the management of hepatitis C virus infection among people who inject drugs
Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade
Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands
Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia
Human rights and access to hepatitis C treatment for people who inject drugs
Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs
Harm reduction for young people who use prescription opioids extra-medically
Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs
Initiating HCV treatment with direct acting agents in opioid agonist treatment
Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting
Understanding real-world adherence in the directly acting antiviral era
What is low threshold methadone maintenance treatment
HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies, 1985–2015
Restrictions on access to direct-acting antivirals for people who inject drugs
Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting
Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs
Managing expense and expectation in a treatment revolution
Defining populations and injecting parameters among people who inject drugs
Hepatitis C testing in general practice settings
Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs
Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
Risk Factors for HCV Infection Among Young Adults in Rural New York Who Inject Prescription Opioid Analgesics
A Randomized Trial of a Hepatitis Care Coordination Model in Methadone Maintenance Treatment
Individual and Network Factors Associated With Prevalent Hepatitis C Infection Among Rural Appalachian Injection Drug Users
A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups
| Obras citantes distintas | 18 |
|---|---|
| Citas por año | 2,25 |
| Intervalo de citas | 2018 - 2023 (6) |
| Velocidad de citación | historical |
| Altamente citado | No |
| Tipos de cita | Neutras: 18 |